
LabGenius develops next-generation antibody and protein therapeutics to improve selectivity and tumor cell killing. The company applies a machine learning–driven evolution engine (EVA) that combines artificial intelligence, synthetic biology, and robotic automation to design, evolve, and screen antibody sequences. EVA is modality- and format-agnostic and supports LabGenius’s internal pipeline focused on selectivity-enhanced antibodies for solid tumors. The platform integrates ML models, high-throughput wet lab automation, and synthetic construct libraries to accelerate discovery and lead optimization. LabGenius advances a pipeline of therapeutic antibody candidates toward clinical development for oncology.

LabGenius develops next-generation antibody and protein therapeutics to improve selectivity and tumor cell killing. The company applies a machine learning–driven evolution engine (EVA) that combines artificial intelligence, synthetic biology, and robotic automation to design, evolve, and screen antibody sequences. EVA is modality- and format-agnostic and supports LabGenius’s internal pipeline focused on selectivity-enhanced antibodies for solid tumors. The platform integrates ML models, high-throughput wet lab automation, and synthetic construct libraries to accelerate discovery and lead optimization. LabGenius advances a pipeline of therapeutic antibody candidates toward clinical development for oncology.
Headquarters & founding: London; founded 2012
Core tech: EVA™ — ML-driven discovery engine combining machine learning, synthetic biology, and robotic automation
Focus: Discovery and optimisation of therapeutic antibodies for oncology (selectivity-enhanced antibodies, multispecific formats, T-cell engagers)
Recent financing: Series B £35M closed May 21, 2024 (led by M Ventures); company-reported total funding ~£58M
| Company |
|---|
Therapeutic antibody discovery and optimisation for oncology
2012
Biotechnology Research
£35,000,000
Company reported this round brought total funding to ~£58M
“Includes corporate VC and top-tier venture investors (M Ventures lead; participation from Octopus Ventures, LG, Atomico, Kindred Capital, Lux Capital, Obvious Ventures)”
At LabGenius, our mission is to accelerate the discovery of next-generation therapeutic antibodies. To do this, we’ve pioneered the development of EVA™ - a smart robotic platform that’s capable of designing, conducting and, critically, learning from its own experiments.
For our wholly-owned pipeline, we’re using our closed-loop discovery engine to establish a pipeline of highly selective T-cell engagers and ADCs for the treatment of solid tumours.
LabGenius has raised >£58M and is backed by top-tier investors, including M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital and Obvious Ventures amongst others.
The company is headquartered in London (UK) where we’ve established a state-of-the-art antibody engineering facility. The company is staffed by a multidisciplinary team of more than 50 scientists and engineers.
As a Data Scientist at LabGenius, you will provide end-to-end data science support for at least one therapeutic asset as we aim to progress from lead discovery all the way to clinical trials. You will drive the “design” and “learn” cycles of the “design-build-test-learn” that forms the basis of our therapeutic antibody optimisation cycles at LabGenius, including the proposal of candidates for rapid experimental characterisation. You will represent data science in highly cross-functional teams, including wet lab scientists (lead optimisation, antibody engineering, assay, and automation), scientific program leads, and software developers. You will onboard rigorous data pipelines, analyses, and visualisations for experiments that allow us to better understand the therapeutic potential of our antibodies. You will enable a data-first ecosystem at LabGenius through your proficiency at processing complex datasets and extracting key insights.
Our Data Science and Machine Learning team pushes the boundaries of therapeutic antibody optimisation by integrating novel DS/ML tooling with our leading experimental laboratory. We oversee the design and optimisation of both monovalent VHHs and multivalent T-cell engagers, including the analyses of experimental data and subsequent ML modelling. At LabGenius, these models allow us to design molecules with previously unexplored therapeutic potential.
What You’ll Do In This Role
What We’re Looking For
What You’ll Receive From Us Aside from being part of our brilliant, purpose-driven team, you’ll also enjoy:
Financial 💸
Health 🍏
Time-Off ⏰
Wellbeing 💛
Team-building 🤝
Diversity & Inclusion We believe that diversity makes for innovative, exceptional teams.
We are an equal opportunity employer and do not discriminate based on gender, race, colour, religion or belief, national origin, age, sexual orientation, marital status, disability, or any other protected class.
If you don't feel like you meet every single requirement of this role, we still want to hear from you! We encourage you to apply, have a discussion with us about the role or others that we may have at LabGenius either now or in the future, together we can build more inclusive workplaces.